How did APLS's Q4 earnings surprise impact its annual performance?
4/10/2025 04:47pm
Apellis Pharmaceuticals (APLS) experienced a significant decline in net income over the past three years, with a cumulative loss of $1.378 billion from 2022 to 2024. However, the company's Q4 2024 earnings surprise, with an EPS surprise of $0.08, had a positive impact on its annual performance, as it marked a shift towards profitability after three consecutive quarters of losses.